Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Top 11 Ways You Can Advocate

Neal S. Birnbaum, MD  |  Issue: August 2007  |  August 1, 2007

Neal S. Birnbaum, MD

Yes, that’s me with Senator Edward M. “Ted” Kennedy (D-Mass.) in Washington, D.C., this past May (at right). As we reported in The Rheumatologist last month, members of the ACR board of directors and I spent the morning of May 10 meeting with our members of Congress on Capitol Hill. Our visits were well received, and we met with representatives or their staff from over 60 offices. It was an opportunity to talk about the issues of importance to rheumatology, and yes, for a photo or two.

Access to a sitting senator, and one of such esteem and influence (whatever your politics may be), doesn’t always come easy. We were able to arrange this meeting because of a personal contact of mine who knows the senator’s former chief of staff. But our meeting with Sen. Kennedy was more than just a photo op: this 45-year veteran of politics spent more than thirty minutes with us, keenly aware of the issues facing medicine and the patients we treat. At the end of our meeting, he even asked for our opinion on the issue of follow-on biologics (aka generic biologics).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

ACR President Neal S. Birnbaum, MD, (left) and Massachusetts Senator Edward Kennedy.

Why I Care so Much

In June, I spoke about why I still like being a rheumatologist – the “still” being in reference as much to the current environment of medicine and all of its hassles as it was to my three decades of being in practice. That column touched a chord with many of you, and you took time out of your day to write me and tell me why you still like being a rheumatologist. Many of you also touched on the hassles of practicing medicine today, and lamented that it didn’t seem like it was going to change any time soon.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

I’m often asked why I spend time volunteering for the ACR and organized medicine. It’s enlightened self-interest more than anything: it is unlikely that anyone will look out for me better than I can look out for myself. I have to be a part of trying to make positive changes in medicine, for rheumatology and for our patients. I don’t see it as a choice, and it is not in me to abdicate this responsibility to others.

You see, the solution to these issues lie in our ability to effectively (and tirelessly) advocate. It’s an inescapable part of our existence in today’s world. The world is divided into two kinds of people: observers and participants. As a rheumatologist or a healthcare professional, if you’re complaining about the state of medicine today, you need to be a participant in the efforts to address and resolve these issues.

Page: 1 2 3 | Single Page
Share: 

Filed under:Legislation & AdvocacyPresident's Perspective Tagged with:AdvocacyAdvocates for ArthritisLegislationPolitics

Related Articles

    State of RheumPAC: 2015 Annual Report

    May 13, 2016

    Dear Friends and Colleagues, With your strong support and commitment, RheumPAC has grown again for the eighth straight year, allowing us to do even more on your behalf. Not only did we exceed our original goal by raising more than $150,000. More importantly, these donations came from nearly 350 ACR and ARHP members—a new record….

    Congressional Lawmakers Every Rheumatologist Should Know

    April 1, 2015

    Key leaders, committee members who can influence federal issues relevant to rheumatology

    Former Senator Tim Hutchinson Urges ACR Members to Advocate for Rheumatology on Local, State and Federal Levels

    January 19, 2017

    WASHINGTON, D.C.—“Regardless of where we are on the political spectrum, we have to get engaged,” said Sen. Tim Hutchinson, senior director, Greenberg Traurig LLP, Washington, D.C., speaking at the 2016 ACR/ARHP Annual Meeting. As a former U.S. senator from Arkansas, Sen. Hutchinson talked about the importance of members in such organizations as the ACR to…

    ACR Leaders to Talk Policy with Congressional Leaders in D.C.

    April 19, 2017

    On May 11, ACR leaders will fly to Capitol Hill to meet with Congressional leaders on behalf of ACR and ARHP members. With so many pressing policy issues facing the medical community this year, we hope that you, too, will let your members of Congress know where you stand on the following issues: Support Medical…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences